Could fewer shots keep myeloma at bay? new trial tests cost-saving approach

NCT ID NCT07485647

Not yet recruiting Disease control Sponsor: Eden Biltibo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can work as well as the standard schedule for multiple myeloma patients after a stem cell transplant. The goal is to reduce costs and clinic visits while maintaining disease control. The study will enroll 50 adults aged 18-70 who have responded well to initial treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab and lenalidomide
What this could lead to: If successful, this could show that less frequent dosing of daratumumab is just as effective, reducing treatment burden and costs for multiple myeloma patients.
What could go wrong: This is a small, early-phase trial (50 participants) testing a reduced schedule. It may not prove non-inferiority, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States

Contact

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.